Harmony Biosciences Holdings Stock EBITDA
| HRMY Stock | USD 29.52 0.02 0.07% |
Harmony Biosciences Holdings fundamentals help investors to digest information that contributes to Harmony Biosciences' financial success or failures. It also enables traders to predict the movement of Harmony Stock. The fundamental analysis module provides a way to measure Harmony Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harmony Biosciences stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 231.3 M | 242.8 M |
Harmony | EBITDA |
Harmony Biosciences Holdings Company EBITDA Analysis
Harmony Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Harmony Biosciences EBITDA | 231.28 M |
Most of Harmony Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harmony Biosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Harmony EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Harmony Biosciences is extremely important. It helps to project a fair market value of Harmony Stock properly, considering its historical fundamentals such as EBITDA. Since Harmony Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harmony Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harmony Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Harmony Ebitda
Ebitda |
|
According to the company disclosure, Harmony Biosciences Holdings reported earnings before interest,tax, depreciation and amortization of 231.28 M. This is 73.64% lower than that of the Pharmaceuticals sector and 130.92% higher than that of the Health Care industry. The ebitda for all United States stocks is 94.07% higher than that of the company.
Harmony EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harmony Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics of similar companies.Harmony Biosciences is currently under evaluation in ebitda category among related companies.
Harmony Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Harmony Biosciences from analyzing Harmony Biosciences' financial statements. These drivers represent accounts that assess Harmony Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harmony Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.4B | 2.1B | 2.5B | 3.3B | 1.9B | 1.8B | |
| Enterprise Value | 2.4B | 2.0B | 2.4B | 3.2B | 1.8B | 1.8B |
Harmony Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Harmony Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Harmony Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Harmony Biosciences' value.| Shares | Dimensional Fund Advisors, Inc. | 2023-12-31 | 736.3 K | Macquarie Group Ltd | 2023-12-31 | 575.6 K | Goldman Sachs Group Inc | 2023-12-31 | 542.2 K | Abrdn Plc | 2023-12-31 | 533.2 K | Federated Hermes Inc | 2023-12-31 | 525.3 K | Massachusetts Financial Services Company | 2023-12-31 | 508.6 K | Nuveen Asset Management, Llc | 2023-12-31 | 402.7 K | Northern Trust Corp | 2023-12-31 | 331.5 K | 683 Capital Management Llc | 2023-12-31 | 325 K | Valor Management Llc | 2023-12-31 | 11.2 M | Blackrock Inc | 2023-12-31 | 6 M |
Harmony Fundamentals
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 56.77 M | ||||
| Shares Owned By Insiders | 19.30 % | ||||
| Shares Owned By Institutions | 90.04 % | ||||
| Number Of Shares Shorted | 6.35 M | ||||
| Price To Earning | 293.37 X | ||||
| Price To Book | 3.59 X | ||||
| Price To Sales | 2.88 X | ||||
| Revenue | 582.02 M | ||||
| Gross Profit | 354.37 M | ||||
| EBITDA | 231.28 M | ||||
| Net Income | 128.85 M | ||||
| Cash And Equivalents | 254.17 M | ||||
| Cash Per Share | 4.30 X | ||||
| Total Debt | 193.57 M | ||||
| Debt To Equity | 0.79 % | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 8.23 X | ||||
| Cash Flow From Operations | 219.39 M | ||||
| Short Ratio | 15.28 X | ||||
| Earnings Per Share | 2.13 X | ||||
| Target Price | 41.63 | ||||
| Number Of Employees | 246 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 1.68 B | ||||
| Total Asset | 811.45 M | ||||
| Retained Earnings | (143.28 M) | ||||
| Working Capital | 287.29 M | ||||
| Net Asset | 811.45 M |
About Harmony Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harmony Biosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Harmony Biosciences Piotroski F Score and Harmony Biosciences Altman Z Score analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Harmony Stock analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Harmony Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harmony Biosciences. If investors know Harmony will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harmony Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 2.13 | Revenue Per Share 9.787 | Quarterly Revenue Growth 0.313 | Return On Assets 0.1616 |
The market value of Harmony Biosciences is measured differently than its book value, which is the value of Harmony that is recorded on the company's balance sheet. Investors also form their own opinion of Harmony Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Harmony Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harmony Biosciences' market value can be influenced by many factors that don't directly affect Harmony Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harmony Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harmony Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harmony Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.